TOR Serine-Threonine Kinases
"TOR Serine-Threonine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine threonine kinase that controls a wide range of growth-related cellular processes. The protein is referred to as the target of RAPAMYCIN due to the discovery that SIROLIMUS (commonly known as rapamycin) forms an inhibitory complex with TACROLIMUS BINDING PROTEIN 1A that blocks the action of its enzymatic activity.
| Descriptor ID |
D058570
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.931 D12.776.476.925
|
| Concept/Terms |
TOR Serine-Threonine Kinases- TOR Serine-Threonine Kinases
- Kinases, TOR Serine-Threonine
- Serine-Threonine Kinases, TOR
- TOR Serine Threonine Kinases
- Target of Rapamycin Proteins
- Rapamycin Proteins Target
- mTOR Serine-Threonine Kinases
- Kinases, mTOR Serine-Threonine
- Serine-Threonine Kinases, mTOR
- mTOR Serine Threonine Kinases
- Mechanistic Target of Rapamycin Protein
- FK506 Binding Protein 12-Rapamycin Associated Protein 1
- FK506 Binding Protein 12 Rapamycin Associated Protein 1
- TOR Kinases
- FKBP12-Rapamycin Associated Protein
- Associated Protein, FKBP12-Rapamycin
- FKBP12 Rapamycin Associated Protein
- Protein, FKBP12-Rapamycin Associated
- FKBP12-Rapamycin Complex-Associated Protein
- Complex-Associated Protein, FKBP12-Rapamycin
- FKBP12 Rapamycin Complex Associated Protein
- Protein, FKBP12-Rapamycin Complex-Associated
- RAFT-1 Protein
- Protein, RAFT-1
- RAFT 1 Protein
- Rapamycin Target Protein
- Protein, Rapamycin Target
- Target Protein, Rapamycin
- mTOR Protein
- Protein, mTOR
|
Below are MeSH descriptors whose meaning is more general than "TOR Serine-Threonine Kinases".
Below are MeSH descriptors whose meaning is more specific than "TOR Serine-Threonine Kinases".
This graph shows the total number of publications written about "TOR Serine-Threonine Kinases" by people in this website by year, and whether "TOR Serine-Threonine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 4 | 4 |
| 2004 | 0 | 13 | 13 |
| 2005 | 0 | 13 | 13 |
| 2006 | 0 | 17 | 17 |
| 2007 | 0 | 26 | 26 |
| 2008 | 0 | 36 | 36 |
| 2009 | 1 | 35 | 36 |
| 2010 | 20 | 34 | 54 |
| 2011 | 22 | 14 | 36 |
| 2012 | 33 | 31 | 64 |
| 2013 | 26 | 23 | 49 |
| 2014 | 28 | 27 | 55 |
| 2015 | 25 | 29 | 54 |
| 2016 | 20 | 35 | 55 |
| 2017 | 13 | 21 | 34 |
| 2018 | 9 | 19 | 28 |
| 2019 | 10 | 17 | 27 |
| 2020 | 9 | 11 | 20 |
| 2021 | 8 | 6 | 14 |
| 2022 | 0 | 11 | 11 |
| 2023 | 1 | 12 | 13 |
| 2024 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "TOR Serine-Threonine Kinases" by people in Profiles.
-
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol. 2024 Apr; 25(4):474-487.
-
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.
-
CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon. JCI Insight. 2024 Jan 23; 9(2).
-
Mammalian target of rapamycin inhibitors: A new-possible approach for in-utero medication therapy. Prenat Diagn. 2024 01; 44(1):88-98.
-
GSK-3? as a Potential Coordinator of Anabolic and Catabolic Pathways in Hepatitis C Virus Insulin Resistance. Intervirology. 2024; 67(1):6-18.
-
Unlocking the miRNA-34a-5p/TGF-? and HMGB1/PI3K/Akt/mTOR crosstalk participate in the enhanced cardiac protection of liraglutide against isoproterenol-induced acute myocardial injury rat model. Int Immunopharmacol. 2024 Jan 25; 127:111369.
-
Angiotensin 1-7 exerts antioxidant effects, suppresses Mammalian Target of Rapamycin (mTOR) signaling, and inhibits apoptosis in renal proximal tubular cells. Peptides. 2024 Feb; 172:171136.
-
Targeted suppression of mTORC2 reduces seizures across models of epilepsy. Nat Commun. 2023 11 14; 14(1):7364.
-
Dominant negative variants in KIF5B cause osteogenesis imperfecta via down regulation of mTOR signaling. PLoS Genet. 2023 Nov; 19(11):e1011005.
-
HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study. Urol Oncol. 2023 12; 41(12):486.e15-486.e23.